Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: Association with outcome and predictive nomogram

Oncologist

Volumn 17, Issue 12, 2012, Pages 1508-1514

  Keizman, Daniel ^a   Gottfried, Maya ^a   Ish Shalom, Maya ^a   Maimon, Natalie ^a   Peer, Avivit ^b   Neumann, Avivit ^b   Rosenbaum, Eli ^c   Kovel, Svetlana ^d   Pili, Roberto ^e   Sinibaldi, Victoria ^f   Carducci, Michael A ^f   Hammers, Hans ^f   Eisenberger, Mario A ^f   Sella, Avishay ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d Asaf Harofe Medical Center   (Israel)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Ketoconazole treatment; Metastatic castration resistant prostate cancer; Neutrophil to lymphocyte ratio; Outcome; Predictive nomogram

Indexed keywords

DOCETAXEL; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BEDTIME DOSAGE; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; HUMAN; LIVER TOXICITY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORNING DOSAGE; NAUSEA; NEUTROPHIL; ORCHIECTOMY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; KETOCONAZOLE; LOGISTIC MODELS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; NOMOGRAMS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE; TREATMENT OUTCOME;

EID: 84871598079     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0125     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596-1605.
3. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339: 1036-1042.
4. Reid AH, Attard G, Barrie E et al. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610-620.
5. Taplin ME, Regan MM, Ko YJ et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res 2009;15: 7099-7105.
6. Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: Further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 2009;100:671-675.
7. Yap TA, Carden CP, Attard G et al. Targeting CYP17: Established and novel approaches in prostate cancer. Curr Opin Pharmacol 2008;8:449-457.
8. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-2825.
9. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-4454.
10. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-6415.
11. Dreicer R, Carducci M. E-1899: An Eastern Cooperative Oncology Group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. Rev Urol 2003;5(suppl 2):S35-S41.
12. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients:A phase III trial (CALGB 9583). J Clin Oncol 2004;22: 1025-1033.
13. Ryan CJ, Weinberg V, Rosenberg J et al. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: Effect of extent of disease on outcome. J Urol 2007;178:2372-2376; discussion 2377.
14. Small EJ, Baron AD, Fippin L et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157:1204-1207.
15. Scholz M, Jennrich R, Strum S et al. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 2005;173:1947-1952.
16. Ryan CJ, Halabi S, Ou SS et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: Results from a Cancer and Leukemia Group B study. Clin Cancer Res 2007;13:2030-2037.
17. Keizman D, Huang P, Carducci M et al. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: Clinical factors associated with PSA response and disease progression. Prostate 2012;72:461-467.
18. Mantovani A, Allavena P, Sica A et al. Cancerrelated inflammation. Nature 2008;454:436-444.
19. Jarnicki A, Putoczki T, Ernst M. Stat3: Linking inflammation to epithelial cancer-more than a "gut" felling? Cell Div 2010;5:14.
20. Gueron G, De Siervi A, Vazquez E. Advanced prostate cancer: Reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 2012;15:213-221.
21. Kao SC, Pavlakis N, Harvie R et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-5813.
22. Kishi Y, Kopetz S, Chun YS et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009;16:614-622.
23. An X, Ding PR, Li YH et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15:516-522.
24. Cho H, Hur HW, Kim SW et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15-23.
25. Yamanaka T, Matsumoto S, Teramukai S et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-220.
26. Keizman D, Ish-Shalom M, Huang P et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012;48:202-208.
27. Gomella LG. Effective testosterone suppression for prostate cancer: Is there a best castration therapy? Rev Urol 2009;11:52-60.
28. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
29. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-1159.
30. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-247.
31. Keizman D, Rogowski O, Berliner S et al. Lowgrade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009;119:383-389.
32. McArdle PA, Mir K, Almushatat AS et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006;77:127-129.
33. Prins RC, Rademacher BL, Mongoue-Tchokote S et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results. Urol Oncol 2012;30:33-37.
34. Pond GR, Armstrong AJ, Wood BA et al. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int 2012 Apr 23 [Epub ahead of print]. doi: 10.1111/j.1464-410X.2012.11148.x.
35. Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20: 3972-3982.
36. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309.
37. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormonerefractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232-1237.
38. Bournakis E, Efstathiou E, Varkaris A et al. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res 2011;31:1475-1482.